Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
K-BOOST: KORTUC (KRC-01) with radiotherapy for locally advanced rectal cancer
2025-524378-40-00Phase 2Authorised
- Sponsor
- Gustave Roussy
- Start
- Oct 2026
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of KRC-01 in rectal adenocarcinoma, sponsored by Gustave Roussy. Primary endpoint: Clinical complete response rate at week 24. Planned start Oct 2026; status: authorised.
02
Drugs
KRC-01
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on 2025-524378-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524378-40-00.